Literature DB >> 24025411

Advances in the understanding of the Fanconi anemia tumor suppressor pathway.

Anna Pickering1, Jun Zhang2, Jayabal Panneerselvam1, Peiwen Fei1.   

Abstract

Extremely high cancer incidence in Fanconi anemia (FA) patients has long suggested that the FA signaling pathway is a tumor suppressor pathway. Indeed, our recent findings, for the first time, indicate that the FA pathway plays a significant role in suppressing the development of non-FA human cancer. Also our studies on FA group D2 protein (FANCD2) have, among the first, documented the crosstalks between the FA and Rad6/Rad18 (HHR6) pathways upon DNA damage. In this review, we will discuss how our studies enhance the understanding of the FA tumor suppressor pathway.

Entities:  

Keywords:  DNA damage; DNA polymerase eta; Rad6/Rad18 pathway; non-FA human tumors; the FA tumor suppressor pathway; translesion synthesis

Mesh：

Substances：

Year:  2013        PMID： 24025411      PMCID： PMC3912030          DOI： 10.4161/cbt.26380

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  41 in total

1.  A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M.

Authors:  Amom Ruhikanta Meetei; Annette L Medhurst; Chen Ling; Yutong Xue; Thiyam Ramsing Singh; Patrick Bier; Jurgen Steltenpool; Stacie Stone; Inderjeet Dokal; Christopher G Mathew; Maureen Hoatlin; Hans Joenje; Johan P de Winter; Weidong Wang
Journal:  Nat Genet       Date:  2005-08-21       Impact factor: 38.330

2.  BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.

Authors:  Rachel Litman; Min Peng; Zhe Jin; Fan Zhang; Junran Zhang; Simon Powell; Paul R Andreassen; Sharon B Cantor
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

3.  Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

Authors:  Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

4.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

Authors:  Bing Xia; Qing Sheng; Koji Nakanishi; Akihiro Ohashi; Jianmin Wu; Nicole Christ; Xinggang Liu; Maria Jasin; Fergus J Couch; David M Livingston
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

5.  Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells.

Authors:  Jun Zhang; Xianshu Wang; Chia-Ju Lin; Fergus J Couch; Peiwen Fei
Journal:  Cancer Biol Ther       Date:  2006-12-05       Impact factor: 4.742

Review 6.  Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.

Authors:  Weidong Wang
Journal:  Nat Rev Genet       Date:  2007-09-04       Impact factor: 53.242

7.  Regulation of monoubiquitinated PCNA by DUB autocleavage.

Authors:  Tony T Huang; Sebastian M B Nijman; Kanchan D Mirchandani; Paul J Galardy; Martin A Cohn; Wilhelm Haas; Steven P Gygi; Hidde L Ploegh; René Bernards; Alan D D'Andrea
Journal:  Nat Cell Biol       Date:  2006-03-12       Impact factor: 28.824

Review 8.  Molecular pathogenesis of Fanconi anemia: recent progress.

Authors:  Toshiyasu Taniguchi; Alan D D'Andrea
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

9.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

10.  Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.

Authors:  Sarah Reid; Detlev Schindler; Helmut Hanenberg; Karen Barker; Sandra Hanks; Reinhard Kalb; Kornelia Neveling; Patrick Kelly; Sheila Seal; Marcel Freund; Melanie Wurm; Sat Dev Batish; Francis P Lach; Sevgi Yetgin; Heidemarie Neitzel; Hany Ariffin; Marc Tischkowitz; Christopher G Mathew; Arleen D Auerbach; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330
View more
  12 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

2.  A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage.

Authors:  X Chen; L Bosques; P Sung; G M Kupfer
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

3.  Fanconi anemia gene editing by the CRISPR/Cas9 system.

Authors:  Mark J Osborn; Richard Gabriel; Beau R Webber; Anthony P DeFeo; Amber N McElroy; Jordan Jarjour; Colby G Starker; John E Wagner; J Keith Joung; Daniel F Voytas; Christof von Kalle; Manfred Schmidt; Bruce R Blazar; Jakub Tolar
Journal:  Hum Gene Ther       Date:  2015-02       Impact factor: 5.695

4.  Advances in the understanding of Fanconi Anemia Complementation Group D2 Protein (FANCD2) in human cancer.

Authors:  Yihang Shen; Jun Zhang; Herbert Yu; Peiwen Fei
Journal:  Cancer Cell Microenviron       Date:  2015-09-07

5.  Mutated Fanconi anemia pathway in non-Fanconi anemia cancers.

Authors:  Yihang Shen; Yuan-Hao Lee; Jayabal Panneerselvam; Jun Zhang; Lenora W M Loo; Peiwen Fei
Journal:  Oncotarget       Date:  2015-08-21

Review 6.  Molecular and cellular functions of the FANCJ DNA helicase defective in cancer and in Fanconi anemia.

Authors:  Robert M Brosh; Sharon B Cantor
Journal:  Front Genet       Date:  2014-10-21       Impact factor: 4.599

7.  Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate.

Authors:  Jayabal Panneerselvam; Anna Pickering; Bing Han; Liantao Li; Junnian Zheng; Jun Zhang; Yanbin Zhang; Peiwen Fei
Journal:  Oncotarget       Date:  2014-03-15

8.  BLM promotes the activation of Fanconi Anemia signaling pathway.

Authors:  Jayabal Panneerselvam; Hong Wang; Jun Zhang; Raymond Che; Herbert Yu; Peiwen Fei
Journal:  Oncotarget       Date:  2016-05-31

Review 9.  FANCD2 and DNA Damage.

Authors:  Manoj Nepal; Raymond Che; Chi Ma; Jun Zhang; Peiwen Fei
Journal:  Int J Mol Sci       Date:  2017-08-19       Impact factor: 5.923

10.  Involvement of FANCD2 in Energy Metabolism via ATP5α.

Authors:  Panneerselvam Jayabal; Chi Ma; Manoj Nepal; Yihang Shen; Raymond Che; James Turkson; Peiwen Fei
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.